BACKGROUND: Although guidelines recommend against prostate-specific antigen (PSA) screening in elderly men with limited life expectancy, screening is common. OBJECTIVE: We sought to identify medical center characteristics associated with screening in this population. DESIGN/PARTICIPANTS: We conducted a prospective study of 622,262 screen-eligible men aged 70+ seen at 104 VA medical centers in 2003. MAIN MEASURES: Primary outcome was the percentage of men at each center who received PSA screening in 2003, based on VA data and Medicare claims. Men were stratified into life expectancy groups ranging from favorable (age 70-79 with Charlson score = 0) to limited (age 85+ with Charlson score ≥1 or age 70+ with Charlson score ≥4). Medical center characteristics were obtained from the 1999-2000 VA Survey of Primary Care Practices and publicly available VA data sources. KEY RESULTS: Among 123,223 (20%) men with limited life expectancy, 45% received PSA screening in 2003. Across 104 VAs, the PSA screening rate among men with limited life expectancy ranged from 25-79% (median 43%). Higher screening was associated with the following center characteristics: no academic affiliation (50% vs. 43%, adjusted RR = 1.14, 95% CI 1.04-1.25), a ratio of midlevel providers to physicians ≥3:4 (55% vs. 45%, adjusted RR = 1.20, 95% CI 1.09-1.32) and location in the South (49% vs. 39% in the West, adjusted RR = 1.25, 95% CI 1.12-1.40). Use of incentives and high scores on performance measures were not independently associated with screening. Within centers, the percentages of men screened with limited and favorable life expectancies were highly correlated (r = 0.90). CONCLUSIONS: Substantial practice variation exists for PSA screening in older men with limited life expectancy across VAs. The high center-specific correlation of screening among men with limited and favorable life expectancies indicates that PSA screening is poorly targeted according to life expectancy.
BACKGROUND: Although guidelines recommend against prostate-specific antigen (PSA) screening in elderly men with limited life expectancy, screening is common. OBJECTIVE: We sought to identify medical center characteristics associated with screening in this population. DESIGN/PARTICIPANTS: We conducted a prospective study of 622,262 screen-eligible men aged 70+ seen at 104 VA medical centers in 2003. MAIN MEASURES: Primary outcome was the percentage of men at each center who received PSA screening in 2003, based on VA data and Medicare claims. Men were stratified into life expectancy groups ranging from favorable (age 70-79 with Charlson score = 0) to limited (age 85+ with Charlson score ≥1 or age 70+ with Charlson score ≥4). Medical center characteristics were obtained from the 1999-2000 VA Survey of Primary Care Practices and publicly available VA data sources. KEY RESULTS: Among 123,223 (20%) men with limited life expectancy, 45% received PSA screening in 2003. Across 104 VAs, the PSA screening rate among men with limited life expectancy ranged from 25-79% (median 43%). Higher screening was associated with the following center characteristics: no academic affiliation (50% vs. 43%, adjusted RR = 1.14, 95% CI 1.04-1.25), a ratio of midlevel providers to physicians ≥3:4 (55% vs. 45%, adjusted RR = 1.20, 95% CI 1.09-1.32) and location in the South (49% vs. 39% in the West, adjusted RR = 1.25, 95% CI 1.12-1.40). Use of incentives and high scores on performance measures were not independently associated with screening. Within centers, the percentages of men screened with limited and favorable life expectancies were highly correlated (r = 0.90). CONCLUSIONS: Substantial practice variation exists for PSA screening in older men with limited life expectancy across VAs. The high center-specific correlation of screening among men with limited and favorable life expectancies indicates that PSA screening is poorly targeted according to life expectancy.
Authors: Louie E Ross; Ralph J Coates; Nancy Breen; Robert J Uhler; Arnold L Potosky; Donald Blackman Journal: Prev Med Date: 2004-06 Impact factor: 4.018
Authors: Ellen M Janssen; Craig E Pollack; Cynthia Boyd; John F P Bridges; Qian-Li Xue; Antonio C Wolff; Nancy L Schoenborn Journal: Med Decis Making Date: 2019-06-21 Impact factor: 2.583
Authors: Nancy L Schoenborn; Jin Huang; Orla C Sheehan; Jennifer L Wolff; David L Roth; Cynthia M Boyd Journal: J Gen Intern Med Date: 2018-11-06 Impact factor: 5.128
Authors: Craig E Pollack; Pamela R Soulos; Jeph Herrin; Xiao Xu; Nicholas A Christakis; Howard P Forman; James B Yu; Brigid K Killelea; Shi-Yi Wang; Cary P Gross Journal: J Natl Cancer Inst Date: 2017-08-01 Impact factor: 13.506
Authors: Nancy L Schoenborn; Kimberley Lee; Craig E Pollack; Karen Armacost; Sydney M Dy; John F P Bridges; Qian-Li Xue; Antonio C Wolff; Cynthia Boyd Journal: JAMA Intern Med Date: 2017-08-01 Impact factor: 21.873
Authors: Victoria L Tang; Ying Shi; Kathy Fung; Jessica Tan; Roxanne Espaldon; Rebecca Sudore; Melisa L Wong; Louise C Walter Journal: JAMA Intern Med Date: 2016-05-01 Impact factor: 21.873
Authors: Florian R Schroeck; Samuel R Kaufman; Bruce L Jacobs; Yun Zhang; Alon Z Weizer; Jeffrey S Montgomery; Scott M Gilbert; Seth A Strope; Brent K Hollenbeck Journal: Med Care Date: 2013-12 Impact factor: 2.983